Publisher
Springer Science and Business Media LLC
Reference12 articles.
1. Aoki KR, Francis J, Jost WH. Mögliche antinozizeptive Mechanismen von Botulinumtoxin. Schmerz 2006; 20: 381–387.
2. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793–803.
3. Cady RK. Onabotulinumtoxin A in the prevention of migraine. Expert Opin Biol Ther 2010; 10: 289–298.
4. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 808–814.
5. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the doubleblind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921–936.